Characterization of novel dual tandem CD19/BCMA chimeric antigen receptor T cells to potentially treat multiple myeloma

BACKGROUND: Treatment with chimeric antigen receptor (CAR)-engineered T cells directed against the B-cell maturation antigen (BCMA) promoted transient recovery from multiple myeloma (MM). However, the absence of this antigen on immature plasma cells may limit the efficacy of this modality and facili...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Biomark Res
Main Authors: Kang, Liqing, Zhang, Jian, Li, Minghao, Xu, Nan, Qi, Wei, Tan, Jingwen, Lou, Xiaoyan, Yu, Zhou, Sun, Juanjuan, Wang, Zhenkun, Fu, Chengcheng, Tang, Xiaowen, Dai, Haiping, Chen, Jia, Wu, Depei, Yu, Lei
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2020
Teme:
Research
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7222432/
https://ncbi.nlm.nih.gov/pubmed/32435496
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40364-020-00192-6
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki